Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.56 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245581 | 0.86 | MEP1B (0.43) | FOLH1MEP1BHPGDS | |
| SCHEMBL2251929 | 0.84 | MEP1B (0.52) | FOLH1MEP1BFFAR1HPGDS | |
| SCHEMBL2247653 | 0.84 | FOLH1 (0.53) | FOLH1MEP1BFFAR1MAOBMAOA | |
| SCHEMBL2246565 | 0.84 | FOLH1 (0.56) | FOLH1MEP1BHPGDS | |
| SCHEMBL2249535 | 0.84 | MEP1B (0.54) | MEP1BFFAR1HPGDS | |
| SCHEMBL2250379 | 0.84 | FFAR1 (0.54) | MEP1BFFAR1 | |
| SCHEMBL2247506 | 0.83 | FOLH1 (0.52) | FOLH1MEP1BFFAR1 | |
| SCHEMBL2246394 | 0.83 | MEP1B (0.46) | FOLH1MEP1BHPGDS | |
| SCHEMBL2248272 | 0.81 | MEN1 (0.51) | MEP1BMAOBMAOA | |
| SCHEMBL2245669 | 0.81 | MAPK14 (0.49) | MEP1BFFAR1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | FOLH1 17/4885MEP1B 2803/4885FFAR1 3780/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | FOLH1 17/4885MEP1B 2803/4885FFAR1 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.